120 related articles for article (PubMed ID: 28708713)
1. Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.
Bánovčin P; Škorňová I; Samoš M; Schnierer M; Bolek T; Kovář F; Staško J; Kubisz P; Mokáň M
J Cardiovasc Pharmacol; 2017 Oct; 70(4):263-266. PubMed ID: 28708713
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Meah MN; Raftis J; Wilson SJ; Perera V; Garonzik SM; Murthy B; Everlof JG; Aronson R; Luettgen J; Newby DE
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2678-2685. PubMed ID: 32907366
[TBL] [Abstract][Full Text] [Related]
3. Observed Apixaban Anti-Xa Levels in Obese Patients.
Harkness W; Pipitone O; Joss J; Schiedler M; Shagavah S; Moore R; Hsing J
Ann Pharmacother; 2022 Feb; ():10600280221077158. PubMed ID: 35168381
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of factor Xa activity, platelet aggregation, and experimentally induced thrombosis by Sparstolonin B.
Kim N; Jeon C; Kim C; Ryu SH; Lee W; Bae JS
Phytomedicine; 2022 May; 99():153987. PubMed ID: 35183932
[TBL] [Abstract][Full Text] [Related]
5. [Incorporation of direct-acting oral anticoagulants to available therapeutic arsenal: Progress adequately?].
Caballero Requejo C; Urbieta Sanz E; Iniesta Navalón C; Gascón Cánovas JJ
Aten Primaria; 2019 Mar; 51(3):184-185. PubMed ID: 30660438
[No Abstract] [Full Text] [Related]
6. Factor Xa inhibitors in hemodialysis: OK-for now!
Banchs JE
Proc (Bayl Univ Med Cent); 2023; 36(6):744. PubMed ID: 37829211
[No Abstract] [Full Text] [Related]
7. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
9. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment: An Alternative Viewpoint.
Roberts MZ; Farley TM; Owens RE
Pharmacotherapy; 2017 Oct; 37(10):e107-e108. PubMed ID: 28741791
[No Abstract] [Full Text] [Related]
11. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.
Melloni C; Dunning A; Granger CB; Thomas L; Khouri MG; Garcia DA; Hylek EM; Hanna M; Wallentin L; Gersh BJ; Douglas PS; Alexander JH; Lopes RD
Am J Med; 2017 Dec; 130(12):1440-1448.e1. PubMed ID: 28739198
[TBL] [Abstract][Full Text] [Related]
12. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.
Manzoor BS; Lee TA; Sharp LK; Walton SM; Galanter WL; Nutescu EA
Pharmacotherapy; 2017 Oct; 37(10):1221-1230. PubMed ID: 28730619
[TBL] [Abstract][Full Text] [Related]
13. Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.
Noseworthy PA; Yao X; Gersh BJ; Hargraves I; Shah ND; Montori VM
Int J Cardiol; 2017 Oct; 245():174-177. PubMed ID: 28733071
[TBL] [Abstract][Full Text] [Related]
14. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials.
Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P
Int J Stroke; 2017 Aug; 12(6):589-596. PubMed ID: 28730948
[TBL] [Abstract][Full Text] [Related]
15. Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database.
Urbaniak AM; Strøm BO; Krontveit R; Svanqvist KH
Drugs Aging; 2017 Aug; 34(8):635-645. PubMed ID: 28710707
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
[TBL] [Abstract][Full Text] [Related]
17. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
[TBL] [Abstract][Full Text] [Related]
18. Triple therapy with dual antiplatelet treatment and direct oral anticoagulants.
Sorigue M; Sarrate E; Delcastillo J
Eur J Intern Med; 2018 Jan; 47():e20. PubMed ID: 28709709
[No Abstract] [Full Text] [Related]
19. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
Norby FL; Alonso A
J Comp Eff Res; 2017 Sep; 6(6):549-560. PubMed ID: 28737102
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants.
Weitz JI; Jaffer IH; Fredenburgh JC
F1000Res; 2017; 6():985. PubMed ID: 28713563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
